OnCo
technologiesTechnologyPhase 3

CAIX PET (89Zr-girentuximab)

CAIX PET is a scan using an antibody against a protein almost unique to clear-cell kidney cancer, to tell cancer from benign kidney lumps without a biopsy.

ZIRCON phase 3 (2023): sensitivity 86%, specificity 87% for clear-cell RCC in indeterminate renal masses. Telix's TLX250-CDx received an FDA complete response letter in 2025 (manufacturing); resubmission planned. Also a theranostic pair with 177Lu-girentuximab (STARLITE trials).

Generic schematic · not to scale · placeholder for the imaging front
Detector ring · Tracer uptake · 511 keV photon pair

How it works

89Zr-labelled anti-CAIX antibody girentuximab imaged 5 days after injection; CAIX is a HIF target expressed in >95% of clear-cell RCC via VHL loss.

Strengths
  • Non-invasive histology-level specificity
  • Whole-body staging of clear-cell disease
Limitations
  • Five-day imaging delay; 89Zr dose
  • Not yet approved (CRL 2025)

Latest papers

top
Literature trend3 papers in the last 12 monthsHow this is computed
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"CAIX PET" OR ABSTRACT:"CAIX PET" OR TITLE:"89Zr-girentuximab" OR ABSTRACT:"89Zr-girentuximab") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CAIX PET (89Zr-girentuximab), not a curated reading list.

Connected

9top

Pages like this

not linked directly; found by shared links

cancers

1
Renal cell carcinoma

fronts

1
Imaging

technologies

2
Immuno-PETPET (positron emission tomography)

targets

1
HIF-2α

companies

1
Telix Pharmaceuticals

pathways

1
VHL / HIF oxygen sensing

ideas

2
Biomarker-selected adjuvant therapy in RCC (ctDNA, CAIX PET, gene signatures)CAIX theranostics: 89Zr-girentuximab PET and 177Lu/225Ac-girentuximab therapy